169 related articles for article (PubMed ID: 7532878)
1. Changes in the contact system during orthotopic liver transplantation with and without aprotinin.
Segal HC; Hunt BJ; Cottam S; Beard C; Francis JL; Potter D; Tan KC
Transplantation; 1995 Feb; 59(3):366-70. PubMed ID: 7532878
[TBL] [Abstract][Full Text] [Related]
2. Fibrinolytic activity during orthotopic liver transplantation with and without aprotinin.
Segal HC; Hunt BJ; Cottam S; Downing A; Beard C; Francis JL; Potter D; Tan KC
Transplantation; 1994 Dec; 58(12):1356-60. PubMed ID: 7528949
[TBL] [Abstract][Full Text] [Related]
3. Aprotinin in orthotopic liver transplantation: evidence for a prohemostatic, but not a prothrombotic, effect.
Molenaar IQ; Legnani C; Groenland TH; Palareti G; Begliomini B; Terpstra OT; Porte RJ
Liver Transpl; 2001 Oct; 7(10):896-903. PubMed ID: 11679989
[TBL] [Abstract][Full Text] [Related]
4. Hemostasis and blood requirements in orthotopic liver transplantation with and without high-dose aprotinin.
Llamas P; Cabrera R; Gómez-Arnau J; Fernández MN
Haematologica; 1998 Apr; 83(4):338-46. PubMed ID: 9592984
[TBL] [Abstract][Full Text] [Related]
5. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury.
Kuyvenhoven JP; Molenaar IQ; Verspaget HW; Veldman MG; Palareti G; Legnani C; Moolenburgh SE; Terpstra OT; Lamers CB; van Hoek B; Porte RJ
Thromb Haemost; 2004 Mar; 91(3):506-13. PubMed ID: 14983226
[TBL] [Abstract][Full Text] [Related]
6. Coagulation and fibrinolysis in primary biliary cirrhosis compared with other liver disease and during orthotopic liver transplantation.
Segal H; Cottam S; Potter D; Hunt BJ
Hepatology; 1997 Mar; 25(3):683-8. PubMed ID: 9049219
[TBL] [Abstract][Full Text] [Related]
7. Evolution of urokinase-type plasminogen activator (u-PA) and tissue-type plasminogen activator (t-PA) in orthotopic liver transplantation (OLT).
Himmelreich G; Dooijewaard G; Breinl P; Bechstein WO; Neuhaus P; Kluft C; Riess H
Thromb Haemost; 1993 Jan; 69(1):56-9. PubMed ID: 8446939
[TBL] [Abstract][Full Text] [Related]
8. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion.
Wachtfogel YT; Kucich U; Hack CE; Gluszko P; Niewiarowski S; Colman RW; Edmunds LH
J Thorac Cardiovasc Surg; 1993 Jul; 106(1):1-9; discussion 9-10. PubMed ID: 7686593
[TBL] [Abstract][Full Text] [Related]
9. The use of high dose aprotinin in liver transplantation: the influence on fibrinolysis and blood loss.
Grosse H; Lobbes W; Frambach M; von Broen O; Ringe B; Barthels M
Thromb Res; 1991 Aug; 63(3):287-97. PubMed ID: 1720262
[TBL] [Abstract][Full Text] [Related]
10. The effect of epsilon-aminocaproic acid and aprotinin on fibrinolysis and blood loss in patients undergoing primary, isolated coronary artery bypass surgery: a randomized, double-blind, placebo-controlled, noninferiority trial.
Greilich PE; Jessen ME; Satyanarayana N; Whitten CW; Nuttall GA; Beckham JM; Wall MH; Butterworth JF
Anesth Analg; 2009 Jul; 109(1):15-24. PubMed ID: 19535691
[TBL] [Abstract][Full Text] [Related]
11. Transfusion requirements are correlated with the degree of proteolysis of von Willebrand factor during orthotopic liver transplantation.
Lattuada A; Mannucci PM; Chen C; Legnani C; Palareti G
Thromb Haemost; 1997 Aug; 78(2):813-9. PubMed ID: 9268177
[TBL] [Abstract][Full Text] [Related]
12. Coagulation and fibrinolysis in orthotopic liver transplantation: current views and insights.
Porte RJ
Semin Thromb Hemost; 1993; 19(3):191-6. PubMed ID: 8362248
[TBL] [Abstract][Full Text] [Related]
13. Hemostatic variation during perioperative period of orthotopic liver transplantation without venovenous bypass.
Wang Y; Liu Y; Han R; Zhu Z; Zhang Y; Wang X; Wang L; Shen Z
Thromb Res; 2008; 122(2):161-6. PubMed ID: 18048090
[TBL] [Abstract][Full Text] [Related]
14. The effect of two different doses of aprotinin on hemostasis in cardiopulmonary bypass surgery: similar transfusion requirements and blood loss.
Santamaría A; Mateo J; Oliver A; Litvan H; Murillo J; Souto JC; Fontcuberta J
Haematologica; 2000 Dec; 85(12):1277-84. PubMed ID: 11114135
[TBL] [Abstract][Full Text] [Related]
15. Aprotinin in orthotopic liver transplantation.
Bechstein WO; Riess H; Blumhardt G; Himmelreich G; Jochum M; Gerlach H; Rossaint R; Keck H; Neuhaus P
Semin Thromb Hemost; 1993; 19(3):262-7. PubMed ID: 7689751
[No Abstract] [Full Text] [Related]
16. Control of coagulation and fibrinolysis by plasma proteinase inhibitors.
Travis J; Salvesen G
Behring Inst Mitt; 1983 Aug; (73):56-65. PubMed ID: 6206838
[TBL] [Abstract][Full Text] [Related]
17. The prophylactic use of tranexamic acid and aprotinin in orthotopic liver transplantation: a comparative study.
Dalmau A; Sabaté A; Koo M; Bartolomé C; Rafecas A; Figueras J; Jaurrieta E
Liver Transpl; 2004 Feb; 10(2):279-84. PubMed ID: 14762867
[TBL] [Abstract][Full Text] [Related]
18. [Reduction of blood loss in orthotopic liver transplantation with the use of aprotinin].
Légaré G; Roy A; Dagenais M; Lapointe R; Marleau D; Thuot C
Ann Chir; 1996; 50(8):601-5. PubMed ID: 9035431
[TBL] [Abstract][Full Text] [Related]
19. Detrimental effect of aprotinin ban on amount of blood loss during liver transplantation: single-center experience.
Trzebicki J; Kosieradzki M; Flakiewicz E; Kuzminska G; Wasiak D; Pacholczyk M; Lagiewska B; Lisik W; Kosson D; Kulik A; Chmura A; Lazowski T
Transplant Proc; 2011 Jun; 43(5):1725-7. PubMed ID: 21693266
[TBL] [Abstract][Full Text] [Related]
20. Prospective randomized placebo-controlled trial of aprotinin for elective aortic reconstruction.
Ranaboldo CJ; Thompson JF; Davies JN; Shutt AM; Francis JN; Roath OS; Webster JH; Chant AD
Br J Surg; 1997 Aug; 84(8):1110-3. PubMed ID: 9278654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
